Jonathan C. Fox Sells 5,000 Shares of Eidos Therapeutics Inc (NASDAQ:EIDX) Stock

Eidos Therapeutics Inc (NASDAQ:EIDX) insider Jonathan C. Fox sold 5,000 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $25.03, for a total value of $125,150.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of EIDX stock traded down $0.62 on Friday, reaching $31.21. 152,750 shares of the company were exchanged, compared to its average volume of 129,883. The stock has a market capitalization of $1.15 billion and a PE ratio of -16.78. The company has a debt-to-equity ratio of 0.01, a current ratio of 19.04 and a quick ratio of 19.04. Eidos Therapeutics Inc has a one year low of $8.89 and a one year high of $32.96.

Eidos Therapeutics (NASDAQ:EIDX) last announced its quarterly earnings results on Monday, April 15th. The company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.01). On average, analysts anticipate that Eidos Therapeutics Inc will post -1.6 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its position in Eidos Therapeutics by 112.9% in the 1st quarter. JPMorgan Chase & Co. now owns 3,947 shares of the company’s stock valued at $93,000 after acquiring an additional 2,093 shares in the last quarter. BNP Paribas Arbitrage SA bought a new position in Eidos Therapeutics in the 1st quarter valued at about $80,000. Citigroup Inc. lifted its position in Eidos Therapeutics by 264.7% in the 1st quarter. Citigroup Inc. now owns 4,873 shares of the company’s stock valued at $114,000 after acquiring an additional 3,537 shares in the last quarter. Northern Trust Corp lifted its position in Eidos Therapeutics by 5.1% in the 4th quarter. Northern Trust Corp now owns 94,601 shares of the company’s stock valued at $1,301,000 after acquiring an additional 4,594 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new position in Eidos Therapeutics in the 4th quarter valued at about $69,000. 34.01% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have weighed in on EIDX shares. BMO Capital Markets initiated coverage on Eidos Therapeutics in a report on Friday, February 22nd. They set an “outperform” rating and a $28.00 price target for the company. JPMorgan Chase & Co. raised shares of Eidos Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Wednesday, February 27th. Zacks Investment Research cut shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 9th. Finally, BTIG Research initiated coverage on shares of Eidos Therapeutics in a research report on Wednesday, April 17th. They set a “buy” rating and a $38.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Eidos Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $30.29.

TRADEMARK VIOLATION NOTICE: This report was first reported by Rockland Register and is owned by of Rockland Register. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://rocklandregister.com/2019/05/31/insider-selling-eidos-therapeutics-inc-eidx-insider-sells-125150-00-in-stock.html.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Recommended Story: Recession

Insider Buying and Selling by Quarter for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.